GlassScriptPhysician profile
Edward A Sherwin
NPI 1356388367
$814.99
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $194 · 2021: $114.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $298.55 | 2019-2021 | |
| Abbvie INC. | $178.86 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.29 | 2019-2020 | |
| Pfizer INC. | $48.58 | 2019-2020 | |
| Gilead Sciences, INC. | $46.07 | 2019-2020 | |
| Allergan, INC. | $31.74 | 2019 | |
| Merck Sharp & Dohme LLC | $28.34 | 2019 | |
| Daiichi Sankyo INC. | $18.75 | 2019 | |
| Shionogi INC | $16.87 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.77 | 2019 | |
| Boston Scientific Corporation | $14.99 | 2021 | |
| Alfasigma USA, INC. | $13.18 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Sherwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.